Quick answer: Three names dominate English-language conversations about weight-loss peptides in Thailand: semaglutide, tirzepatide and retatrutide. All act on hormone-signalling pathways related to weight regulation, but they do not have the same receptor targets or development status. Human studies have produced impressive results, particularly for tirzepatide and the investigational compound retatrutide.
Why GLP-1-related peptides draw attention
GLP-1-related medicines helped establish that hormone-based approaches can produce clinically meaningful changes in weight. Semaglutide acts on the GLP-1 receptor; tirzepatide acts on GIP and GLP-1 receptors; retatrutide has been investigated as a GIP, GLP-1 and glucagon triple agonist. These different targets are central to the research interest. They are not interchangeable products.
Results from important human trials
| Compound | Trial finding | Research context |
|---|---|---|
| Semaglutide | 13.7% mean reduction after 72 weeks in SURMOUNT-5 | Direct comparison with tirzepatide |
| Tirzepatide | 20.2% mean reduction after 72 weeks in SURMOUNT-5 | Direct comparison with semaglutide |
| Retatrutide | 24.2% mean reduction after 48 weeks in the 12-mg group in Phase 2 | Separate study, not head-to-head with the other two |
| Retatrutide | 28.3% average reduction at 80 weeks in a Phase 3 topline announcement | Manufacturer-reported TRIUMPH-1 result; assess full peer-reviewed details as available |
The 72-week head-to-head trial directly supports a tirzepatide-versus-semaglutide comparison within its studied population. Retatrutide's figures come from different trials and durations and cannot be ranked as a fair head-to-head comparison.
Tirzepatide vs semaglutide: what was impressive?
In the peer-reviewed SURMOUNT-5 study, 751 adults with obesity and without diabetes were randomized to receive one of the two medicines. Both groups experienced substantial average weight reduction; the trial reported 20.2% for tirzepatide compared with 13.7% for semaglutide at 72 weeks. Waist circumference changes were also greater in the tirzepatide group.
Those are study averages, and individuals vary. The trial also documented gastrointestinal adverse events. The result is a strong example of how researchers can demonstrate benefits through direct comparisons rather than unsupported claims.
Why is everyone talking about retatrutide?
Retatrutide has attracted attention because of its triple-receptor design and striking research results. A published 2023 Phase 2 trial documented average weight reduction of 24.2% after 48 weeks in its 12-mg group. In May 2026, the developer announced 28.3% mean weight loss after 80 weeks for a group in the TRIUMPH-1 Phase 3 trial. The latter was a company topline release, not a direct comparison against marketed GLP-1 medicines.
The cited retatrutide results describe development trials and the preparations studied. They do not verify a separate catalogue item. Read our retatrutide research guide for the study context.
What do users report?
Public discussion among people receiving GLP-1-based treatments often focuses on weight change, appetite and satiety. Those experiences may be useful background, but trial averages are a more dependable way to understand effects. We do not present unverified online stories as testimonials from Bangkok Recovery Lab customers.
Why do Thailand searchers compare product names and formats?
Searching “tirzepatide Thailand” or “retatrutide Bangkok” can bring up scientific articles, clinics and peptide catalogue listings. A chemical name is not a guarantee of the same preparation, clinical testing or intended use. Read our formulation comparison and Formats and product documentation before drawing conclusions from marketing labels.
Frequently asked questions
Which weight-loss peptide has the strongest head-to-head comparison?
The SURMOUNT-5 randomized study directly compared tirzepatide with semaglutide. Retatrutide's major results should be interpreted separately.
Is retatrutide being researched for weight loss?
Yes. It has published Phase 2 data and announced Phase 3 outcomes. That clinical programme is why it features prominently in peptide research discussions.
Are these figures what every user should expect?
No. They are means from particular clinical trial groups. They are not guarantees for individuals or claims about products outside those trials.
Where can I explore compound-specific research?
Start with the retatrutide research guide or the tirzepatide versus retatrutide comparison.
Sources
- NEJM: SURMOUNT-5 head-to-head tirzepatide–semaglutide trial
- NEJM: Retatrutide Phase 2 trial
- Eli Lilly: TRIUMPH-1 Phase 3 topline release, 21 May 2026
- ClinicalTrials.gov: study basics
Educational explanation based on the sources and related guides linked here. Research findings and laboratory results have different scopes. This guide is not medical advice or independent verification of a particular product.